Location [1]
Protein [2]
Bifunctional purine biosynthesis protein PURH, N-terminally processed
Synonyms [1]

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) is a gene that encodes a catalytic protein that catalyzes the final two steps of the de novo purine biosynthetic pathway. Fusions, missense mutations, nonsense mutations, and silent mutations are observed in cancers such as lung cancer, ovarian cancer, and skin cancer.

ATIC is altered in 0.08% of all cancers with lung adenocarcinoma, acute myeloid leukemia, cancer of unknown primary, diffuse large B-cell lymphoma, not otherwise specified, and glioblastoma having the greatest prevalence of alterations [3].

ATIC GENIE Cases - Top Diseases

The most common alteration in ATIC is ATIC-ALK Fusion (0.08%) [3].

ATIC GENIE Cases - Top Alterations


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.